rrobbins

Main Profile

Full Name and Degrees: 

Robert C. Robbins, M.D.

Member Role: 

Affiliated Investigator

More Info: 

President and Chief Executive Officer of the Texas Medical Center

Institutional affiliation: 

Texas Medical Center

Additional links: 

http://texasmedicalcenter.org/about-the-texas-medical-center-corporation/

Research hub: 

iPS Cells in Heart Disease

Hub Site: 

None

research focus: 

Robert C. Robbins, MD
Director, Stanford Cardiovascular Institute

Robert C. Robbins, MD, Professor and Chairman of the Department of Cardiothoracic Surgery, has been a member of the faculty at Stanford University School of Medicine since 1993. He serves as Director of the Stanford Cardiovascular Institute, Director of the Heart, Heart-Lung, and Lung Transplantation programs, and is the Director of the Cardiothoracic Transplantation Laboratory.

Dr. Robbins received his BS degree from Millsaps College in 1979 and MD degree from the University of Mississippi Medical Center in 1983. He completed his general surgical training at the University of MIssissippi Medical Center in 1989. Dr. Robbins completed his Cardiothoracic Surgery Residency at Stanford University in 1992.

Dr. Robbins was a Pediatric Fellow in Cardiothoracic Surgery at Emory University, Atlanta, GA, and Royal Children’s Hospital in Melbourne, Australia. He was a Clinical Associate, Surgery Branch NHLBI at the National Institutes of Health in Bethesda, MD, from 1986-1988. In addition, Dr. Robbins is the Guest Editor for the Surgical Supplement of Circulation and is a manuscript reviewer for a number of periodicals, including the New England Journal of Medicine and Annals of Thoracic Surgery, and serves on the Editorial Board for the Journal of Thoracic and Cardiovascular Surgery. Dr. Robbins is certified by the American Board of Surgery and the American Board of Thoracic Surgery. He served on the Board of Directors for Cohesion Technologies, International Society of Heart and Lung Transplantation from 2000-2003 and President of the society from 2007 to 2008. He currently serves on the Board of Directors for Cardica Inc., Cytograft Tissue Engineering Inc., California Transplant Donor Network, and the Bay Area Society of Thoracic Surgeons. Dr. Robbins serves on Scientific Advisory Boards for medical device companies.

His current research interests include: 

o    the investigation of the immunobiology and factors associated with the in vivo survival of mouse and human embryonic stems used for the treatment of congestive heart failure

o    the study of genetic determinants of congestive heart failure

o    Hemodynamic, MRI, Echocardiographic, and Molecular Imaging assessment of congestive heart failure and cell therapy in mice and rats

o    the investigation of Apelin in congestive heart failure

o    the study of the role of bcl-2 in cardiac allograft vasculopathy

o    the development of automated coronary anastomotic devices

o    and the assessment of tissue engineered blood vessels.

Recent publications: 

Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Nature. 2004; 428 (6983): 668-73 http://med.stanford.edu/profiles/frdActionServlet?choiceId=showPublication&pubid=23851&fid=4247 In vivo functional and transcriptional profiling of bone marrow stem cells after transplantation into ischemic myocardium. Sheikh AY, Huber BC, Narsinh KH, Spin JM, van der Bogt K, de Almeida PE, Ransohoff KJ, Kraft DL, Fajardo G, Ardigo D, Ransohoff J, Bernstein D, Fischbein MP, Robbins RC, Wu JC. Arterioscler Thromb Vasc Biol. 2012; 32 (1): 92-102 http://www.ncbi.nlm.nih.gov/pubmed/22034515?dopt=Abstract&otool=stanford Molecular imaging of bone marrow mononuclear cell survival and homing in murine peripheral artery disease. van der Bogt KE, Hellingman AA, Lijkwan MA, Bos EJ, de Vries MR, van Rappard JR, Fischbein MP, Quax PH, Robbins RC, Hamming JF, Wu JC. JACC Cardiovasc Imaging. 2012; 5 (1): 46-55 http://www.ncbi.nlm.nih.gov/pubmed/22239892?dopt=Abstract&otool=stanford miR-29b Participates in Early Aneurysm Development in Marfan Syndrome. Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP. Circ Res. 2012; 110 (2): 312-24 http://www.ncbi.nlm.nih.gov/pubmed/22116819?dopt=Abstract&otool=stanford novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection.Chin JT, Troke JJ, Kimura N, Itoh S, Wang X, Palmer OP, Robbins RC, Fischbein MP. Yale J Biol Med. 2011; 84 (4): 423-32 http://www.ncbi.nlm.nih.gov/pubmed/22180679?dopt=Abstract&otool=stanford

Profile Page Photo: